Condition (MeSH)
Cataplexy
ClinicalTrials.gov lists 30 trials for Cataplexy or a narrower condition beneath it. Axsome Therapeutics, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
30 of the 30 trials are tagged with Cataplexy itself; the rest are tagged with a narrower condition beneath it.
When did Cataplexy trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2024 | 2 |
| 2023 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2016 | 2 |
| 2013 | 1 |
| 2011 | 2 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cataplexy trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 18 |
| Not applicable | 3 |
| Observational | 4 |
How many Cataplexy trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 24 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cataplexy trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Axsome Therapeutics, Inc. | 3 |
| Alkermes, Inc. | 2 |
| AstraZeneca | 2 |
| Avadel | 2 |
| Cephalon | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Cataplexy? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pitolisant | 5 |
| Samelisant | 2 |
| OKN 007 | 2 |
| Modafinil | 2 |
| Armodafinil | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| AXS-12 (Reboxetine) | 3 |
| FT218 | 2 |
| BF2.649 add on Modafinil | 1 |
| A/H1N1 vaccine | 1 |
| Xyrem (sodium oxybate) oral solution | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cataplexy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Arthritis | 2 | 1 |
| Chest pain | 2 | 1 |
| Osteoarthritis | 2 | 1 |
| Abdominal haematoma | 1 | 1 |
| Angioneurotic oedema | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Cataplexy? (41)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. | The New England journal of medicine | 2025 | Yes |
| Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy. | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2024 | Yes |
| Identification of bidirectional causal links between gut microbiota and narcolepsy type 1 using Mendelian randomization. | Sleep | 2024 | Yes |
| Clinical and neurophysiological characteristics of 89 patients with narcolepsy and cataplexy from the Russian Narcolepsy Network. | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2023 | Yes |
| Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. | The Lancet. Neurology | 2023 | Yes |
Showing 5 of 41 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.